Antitumor agent-65 (Compound 5) is an analogue/derivative of (-)-cleistenolide. Antitumor agent-65 has the potential for the research of cancer diseases^[1].

407.33

C₁₈H₁₇NO₁₀

2456288-82-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Benedeković G, et al. Synthesis, antiproliferative activity and SAR analysis of (-)-cleistenolide and analogues. Eur J Med Chem. 2020 Sep 15;202:112597.

Antitumor agent-56 (Compound 33) is a triptolide derivative with antitumor, anti-inflammatory and NO release activities. Antitumor agent-56 significantly inhibits the growth of melanoma. Antitumor agent-56 is orally active^[1].

584.59

C₂₈H₂₈N₂O₁₀S

2411579-53-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zang Y, et al. Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies. Eur J Med Chem. 2020 Mar 15;190:112079.

Antitumor agent-57 (Compound 3o) is an NQO1-directed antitumor agent. Antitumor agent-57 inhibits tumor cell growth, triggers ROS generation and induces cell apoptosis^[1].

349.34

C₂₀H₁₅NO₅

2432823-48-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wu LQ, et al. Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents. Eur J Med Chem. 2020 Jul 15;198:112396.

Antitumor agent-64 (Compound 8d) is a diosgenin derivative. Antitumor agent-64 exhibits potent cytotoxic activity against A549 cell line. Antitumor agent-64 induces A549 cells apoptosis via the mitochondria-related pathway^[1].

589.83

C₃₅H₄₇N₃O₃S

2396562-55-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang J, et al. Novel diosgenin derivatives containing 1,3,4-oxadiazole/thiadiazole moieties as potential antitumor agents: Design, synthesis and cytotoxic evaluation. Eur J Med Chem. 2020 Jan 15;186:111897.

Antitumor agent-66 (Compound 4) is an analogue/derivative of (-)-cleistenolide. Antitumor agent-66 has the potential for the research of cancer diseases^[1].

396.78

C₁₈H₁₇ClO₈

2456288-81-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Benedeković G, et al. Synthesis, antiproliferative activity and SAR analysis of (-)-cleistenolide and analogues. Eur J Med Chem. 2020 Sep 15;202:112597.

Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues^[1].

apoptosis^[1]

Antitumor agent-36 (compound 1) (24-76 hours) displays relatively lower activities after 24 h treatment, and the IC₅₀ values decreases at 48 h, and the activities at 72 h are similar to that of 48 h^[1].
Antitumor agent-36 (compound 1) (24 hours) induces significant apoptosis of tumor cells.^[1].
Antitumor agent-36 (compound 1) (24 hours) are effective in modulating the expression of apoptotic proteins in tumor cells ^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

804.58

C₃₂H₃₀Cl₂N₂O₆Pt

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li Z, et al. Ketoprofen and Loxoprofen Platinum(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response. J Med Chem. 2021;64(24):17920-17935.

Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues^[1].

apoptosis^[1]

Antitumor agent-36 (compound 1) (24-76 hours) displays relatively lower activities after 24 h treatment, and the IC₅₀ values decreases at 48 h, and the activities at 72 h are similar to that of 48 h^[1].
Antitumor agent-36 (compound 1) (24 hours) induces significant apoptosis of tumor cells.^[1].
Antitumor agent-36 (compound 1) (24 hours) are effective in modulating the expression of apoptotic proteins in tumor cells ^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

804.58

C₃₂H₃₀Cl₂N₂O₆Pt

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li Z, et al. Ketoprofen and Loxoprofen Platinum(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response. J Med Chem. 2021;64(24):17920-17935.

Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues^[1].

apoptosis^[1]

Antitumor agent-37 (compound 7) (24-76 hours) displays relatively lower activities after 24 h treatment, and the IC₅₀ values decreases at 48 h, and the activities at 72 h are similar to that of 48 h^[1].
Antitumor agent-37 (compound 7) (24 hours) induces significant apoptosis of tumor cells in a dose-dependent manner^[1].
Antitumor agent-37 (compound 7) (24 hours) induces serious apoptosis of tumor cells by the activation of mitochondrial pathway Bcl-2/Bax/caspase3^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Antitumor agent-37 (compound 7) (i.p.; 4 mg Pt/kg; four times on days 3, 6, 9, and 12 post-tumor inoculation) exerts no visible impacts on body weight of mice in comparison with the blank group, which is obviously superior to reference drug OLP and complex 9, indicating its low toxicity in vivo^[1].
Antitumor agent-37 (compound 7) (i.p.; 4 mg Pt/kg; four times on days 3, 6, 9, and 12 post-tumor inoculation) also exhibits prominent tumor growth inhibition to 4T1 tumors with a TGI of 54.6%^[1].
Antitumor agent-37 (compound 7) (i.p.; 2 mg Pt/kg; four times on days 2, 4, 6, 8, 10, 12, and 14 post-tumor inoculation) displays significantly more effective antimetastasis effects than CDDP and OLP in vivo^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

568.32

C₁₆H₁₈Cl₂N₂O₄Pt

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li Z, et al. Ketoprofen and Loxoprofen Platinum(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response. J Med Chem. 2021;64(24):17920-17935.

Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues^[1].

apoptosis^[1]

Antitumor agent-37 (compound 7) (24-76 hours) displays relatively lower activities after 24 h treatment, and the IC₅₀ values decreases at 48 h, and the activities at 72 h are similar to that of 48 h^[1].
Antitumor agent-37 (compound 7) (24 hours) induces significant apoptosis of tumor cells in a dose-dependent manner^[1].
Antitumor agent-37 (compound 7) (24 hours) induces serious apoptosis of tumor cells by the activation of mitochondrial pathway Bcl-2/Bax/caspase3^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Antitumor agent-37 (compound 7) (i.p.; 4 mg Pt/kg; four times on days 3, 6, 9, and 12 post-tumor inoculation) exerts no visible impacts on body weight of mice in comparison with the blank group, which is obviously superior to reference drug OLP and complex 9, indicating its low toxicity in vivo^[1].
Antitumor agent-37 (compound 7) (i.p.; 4 mg Pt/kg; four times on days 3, 6, 9, and 12 post-tumor inoculation) also exhibits prominent tumor growth inhibition to 4T1 tumors with a TGI of 54.6%^[1].
Antitumor agent-37 (compound 7) (i.p.; 2 mg Pt/kg; four times on days 2, 4, 6, 8, 10, 12, and 14 post-tumor inoculation) displays significantly more effective antimetastasis effects than CDDP and OLP in vivo^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

568.32

C₁₆H₁₈Cl₂N₂O₄Pt

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li Z, et al. Ketoprofen and Loxoprofen Platinum(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response. J Med Chem. 2021;64(24):17920-17935.

Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues^[1].

apoptosis^[1]

Antitumor agent-36 (compound 1) (24-76 hours) displays relatively lower activities after 24 h treatment, and the IC₅₀ values decreases at 48 h, and the activities at 72 h are similar to that of 48 h^[1].
Antitumor agent-36 (compound 1) (24 hours) induces significant apoptosis of tumor cells.^[1].
Antitumor agent-36 (compound 1) (24 hours) are effective in modulating the expression of apoptotic proteins in tumor cells ^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

804.58

C₃₂H₃₀Cl₂N₂O₆Pt

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li Z, et al. Ketoprofen and Loxoprofen Platinum(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response. J Med Chem. 2021;64(24):17920-17935.

Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues^[1].

apoptosis^[1]

Antitumor agent-37 (compound 7) (24-76 hours) displays relatively lower activities after 24 h treatment, and the IC₅₀ values decreases at 48 h, and the activities at 72 h are similar to that of 48 h^[1].
Antitumor agent-37 (compound 7) (24 hours) induces significant apoptosis of tumor cells in a dose-dependent manner^[1].
Antitumor agent-37 (compound 7) (24 hours) induces serious apoptosis of tumor cells by the activation of mitochondrial pathway Bcl-2/Bax/caspase3^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Antitumor agent-37 (compound 7) (i.p.; 4 mg Pt/kg; four times on days 3, 6, 9, and 12 post-tumor inoculation) exerts no visible impacts on body weight of mice in comparison with the blank group, which is obviously superior to reference drug OLP and complex 9, indicating its low toxicity in vivo^[1].
Antitumor agent-37 (compound 7) (i.p.; 4 mg Pt/kg; four times on days 3, 6, 9, and 12 post-tumor inoculation) also exhibits prominent tumor growth inhibition to 4T1 tumors with a TGI of 54.6%^[1].
Antitumor agent-37 (compound 7) (i.p.; 2 mg Pt/kg; four times on days 2, 4, 6, 8, 10, 12, and 14 post-tumor inoculation) displays significantly more effective antimetastasis effects than CDDP and OLP in vivo^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

568.32

C₁₆H₁₈Cl₂N₂O₄Pt

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li Z, et al. Ketoprofen and Loxoprofen Platinum(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response. J Med Chem. 2021;64(24):17920-17935.

Antitumor agent-39 is a peptide compound with anticancer effect (US20050009751A1, compound 64)^[1].

732.01

C₄₀H₆₉N₅O₇

159255-72-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Peter Senter, et al. Pentapeptide compounds and uses related thereto. US20050009751A1.

Antitumor agent-39 is a peptide compound with anticancer effect (US20050009751A1, compound 64)^[1].

732.01

C₄₀H₆₉N₅O₇

159255-72-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Peter Senter, et al. Pentapeptide compounds and uses related thereto. US20050009751A1.

Antitumor agent-39 is a peptide compound with anticancer effect (US20050009751A1, compound 64)^[1].

732.01

C₄₀H₆₉N₅O₇

159255-72-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Peter Senter, et al. Pentapeptide compounds and uses related thereto. US20050009751A1.

Antitumor agent-49 (Compound 10) is a Harmine derivative-furoxan hybrids containing NO donor, with antitumor activities. Antitumor agent-49 shows cytotoxic activity against HepG2 cells with an IC₅₀ of 1.79 µM. Antitumor agent-49 produces high levels of NO in vitro^[1].

841.77

C₄₂H₄₁BrN₄O₈S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhezhe Li, et al. Synthesis of harmine-nitric oxide donor derivatives as potential antitumor agents. Bioorg Med Chem Lett. 2022 Mar 24;65:128698.

Antitumor agent-47 (Compound 3e) is a silibinin derivative with an antitumor activity. Antitumor agent-47 shows cytotoxic activity against NCI-H1299 and HT29 cells with IC₅₀ values of 8.07 µM and 6.27 µM, respectively^[1].

577.54

C₃₀H₂₇NO₁₁

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Qiuchan Wu, et al. Synthesis and antitumor activity of novel silibinin and 2,3-dehydrosilybin derivatives with carbamate groups. Med Chem Res. 2022;31(4):533-544.